Myriad Genetics (MYGN) Tops Q2 EPS by 4c
Tweet
Share
E-mailGet Alerts MYGN Hot Sheet
Price: $6.03 --0%
Revenue Growth %: -3.3%
Financial Fact:
Cost of molecular diagnostic testing: 34.3M
Today's EPS Names:
EPAC, SAR, KRUS, More
Revenue Growth %: -3.3%
Financial Fact:
Cost of molecular diagnostic testing: 34.3M
Today's EPS Names:
EPAC, SAR, KRUS, More
Join SI Premium – FREE
Myriad Genetics (NASDAQ: MYGN) reported Q2 EPS of $0.45, $0.04 better than the analyst estimate of $0.41. Revenue for the quarter came in at $193.3 million versus the consensus estimate of $189.97 million.
For earnings history and earnings-related data on Myriad Genetics (MYGN) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Meta capex to surge in 2027, neocloud fears ’erroneous’ - SemiAnalysis
- Stifel Starts SpaceX (SPCX) at Buy
- Clear Street Starts SpaceX (SPCX) at Buy
Create E-mail Alert Related Categories
EarningsRelated Entities
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
